GELS vs TMO vs STE Stock Comparison

Gelteq, Thermo Fisher Scientific and Steris Prices as of Nov 16, 2026 Peers: Industry group
GELS Gelteq Ltd
$0.36 -20.0% 1M -63.9% 1Y
Market cap
$2.43M
P/E
–
Revenue (TTM)
—
Div. yield
–
Contract Manufacturing Healthcare
STE STERIS plc
$261.89 +17.6% 1M +1.3% 1Y
Market cap
$25.07B
P/E
30.3x
Revenue (TTM)
$6.17B
Div. yield
0.01%
Medical Devices Healthcare
8 wins

Head to Head

12 decided of 12

Steris leads on 8 of the 12 questions below (Steris 8, Thermo Fisher Scientific 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGELSTMOSTELeader
Larger companyMarket capitalisation $2.43M $254.34B $25.07B TMO
Cheaper on earningsLower P/E, profitable companies only — 36.0x 30.3x STE
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 27.0x 22.4x STE
Faster revenue growthRevenue growth, trailing twelve months — +8.3% +8.1% TMO
More profitableNet margin, trailing twelve months — 14.9% 13.4% TMO
Better return on capitalReturn on invested capital — 8.0% 9.5% STE
Less leveragedLower net debt / EBITDA — 3.1x 0.8x STE
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% STE
Better 1-year returnPrice return, last 12 months -63.9% +19.5% +1.3% TMO
Better 5-year returnAnnualised price return, 5 years — +1.7%/yr +2.5%/yr STE
Less volatileAnnualised volatility, 1 year 160.3% 30.7% 26.9% STE
Higher overall scoreMean of the five percentile scores vs peers — 60/100 70/100 STE

Percentile Scorecard

GELSTMOSTE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGELSTMOSTE
Valuation – 62 #94 of 243 73 #67 of 243
Growth – 40 #137 of 228 51 #113 of 228
Profitability – 84 #36 of 222 90 #23 of 222
Financial Health 58 #6 of 13 30 #173 of 248 64 #90 of 248
Shareholder Returns – 82 #29 of 159 75 #41 of 159
Overall – 60 70
  • GELS ranked among 13 companies in Pharma Services
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • STE ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGELSTMOSTESPY
1 month -20.0%+0.2%+17.6% -3.0%
3 months -35.7%+18.1%+14.0% -4.2%
6 months -11.1%+56.5%+23.0% +0.2%
Year to date -55.0%+19.4%+3.3% +8.5%
1 year -63.9%+19.5%+1.3% +10.1%
3 years —+48.3%+30.8% +64.1%
3 years, per year —+14.1%+9.4% +18.0%
5 years —+8.5%+13.1% +58.1%
5 years, per year —+1.7%+2.5% +9.6%
10 years —+362.8%+293.8% +239.6%
10 years, per year —+16.6%+14.7% +13.0%

Risk

MeasureGELSTMOSTESPY
Volatility, 1Y 160.3%30.7%26.9% 13.8%
Downside volatility, 1Y 124.2%29.2%25.5% 14.2%
Beta vs S&P 500, 1Y 1.810.700.39 1.00
Return / volatility, 1Y -0.400.640.05 0.74
Max drawdown, 5Y -92.5%-41.5%-36.5% -25.4%
From 52-week high -76.5%-4.1%-2.5% -5.0%
52-week high $1.53$721.63$268.65 $779.14
52-week low $0.36$438.34$199.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGELSTMOSTE
P/E now vs peer median —median 34.7x 36.6xmedian 26.5x 31.1xmedian 26.5x
P/S now vs peer median —median 2.5x 5.5xmedian 2.7x 4.2xmedian 2.7x
EV/EBITDA now vs peer median —median 29.1x 25.5xmedian 18.6x 16.2xmedian 18.6x
P/FCF now vs peer median -5.7xmedian 21.0x 34.2xmedian 25.6x 27.4xmedian 25.6x
P/B now vs peer median 0.4xmedian 1.6x 4.7xmedian 2.5x 3.5xmedian 2.5x
PEG now vs peer median —median 1.98 4.84median 0.98 2.04median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGELSTMOSTE
Revenue – $47.35B $6.17B
Gross profit – $19.45B $2.75B
Operating income – $8.47B $1.17B
Net income – $7.09B $829.70M
Free cash flow – $7.60B $937.20M
R&D – $1.40B $118.40M
EPS (diluted) – $19.06 $8.47
Cash & equivalents $6.26K $5.46B $531.10M
Total debt $9.08K $41.37B $1.89B
Shares (diluted) 9.27M 371.00M 97.60M
Enterprise value $283.86K $230.85B $23.19B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGELSTMOSTE
P/E – 36.6x 31.1x
P/FCF -5.7x 34.2x 27.4x
P/Operating cash flow – 27.8x 19.9x
P/S – 5.5x 4.2x
P/B 0.4x 4.7x 3.5x
P/Tangible book -1.2x 7.1x 4.4x
EV/EBITDA – 25.5x 16.2x
EV/EBIT – 34.8x 23.1x
EV/Revenue – 6.2x 4.4x
EV/FCF – 38.8x 28.8x
EV/Operating cash flow – 31.6x 21.0x
PEG (3Y EPS CAGR) – 4.84 2.04

Growth

14 metrics
MetricGELSTMOSTE
Revenue growth (1Y) – 8.3% 8.1%
Revenue CAGR (3Y) – 2.9% 8.6%
Gross profit growth (1Y) – 7.8% 8.8%
Gross profit CAGR (3Y) – 4.0% 9.4%
Operating income growth (1Y) – 12.8% 20.2%
Operating income CAGR (3Y) – 7.2% -4.1%
Net income growth (1Y) – 7.9% 20.2%
Net income CAGR (3Y) – 6.2% 14.6%
EPS growth (1Y) – 9.7% 21.6%
EPS CAGR (3Y) – 7.6% 15.3%
Operating cash flow growth (1Y) – 21.9% -0.9%
Operating cash flow CAGR (3Y) – 4.5% 15.0%
Free cash flow growth (1Y) – 24.3% -2.5%
Free cash flow CAGR (3Y) – 5.1% 20.5%

Profitability

14 metrics
MetricGELSTMOSTE
Gross margin – 41.1% 44.6%
EBITDA margin – 24.4% 27.0%
Operating margin – 17.9% 19.0%
Pretax margin – 16.7% 18.2%
Net margin – 14.9% 13.4%
FCF margin – 16.0% 15.2%
Operating cash flow margin – 19.7% 20.9%
Return on equity – 13.2% 11.4%
Return on assets – 6.2% 7.7%
Return on invested capital – 8.0% 9.5%
Return on capital employed – 8.5% 12.3%
Asset turnover – 0.4x 0.6x
Cash conversion (OCF / net income) – 1.3x 1.6x
Stock comp / revenue – 0.7% 1.0%

Financial Health

11 metrics
MetricGELSTMOSTE
Debt / assets 0.1% 36.2% 17.7%
Debt / equity 0.0x 0.8x 0.3x
Net debt / EBITDA – 3.1x 0.8x
Debt / FCF – 5.4x 2.0x
Liabilities / assets 29.4% 52.1% 32.1%
Equity / assets 70.6% 47.9% 67.9%
Interest coverage – 12.0x 20.5x
Current ratio 0.1x 1.8x 2.1x
Quick ratio 0.1x 1.2x 1.3x
Cash ratio 0.0x 0.4x 0.4x
Altman Z-score – 4.18 5.98

Shareholder Returns

7 metrics
MetricGELSTMOSTE
Dividend yield – 0.3% 1.0%
Net buyback yield – 1.6% 1.3%
Shareholder yield – 1.8% 2.3%
Payout ratio (earnings) – 9.5% 30.4%
Payout ratio (FCF) – 8.9% 26.9%
Dividend growth (1Y) – 8.0% 9.5%
Dividend CAGR (3Y) – 10.1% 9.6%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGELSTMOSTE
Forward P/E – 27.0xFY2026 22.4xFY2026
EPS, next fiscal year – $25.92FY2026 $11.78FY2026
EPS growth, next FY – +13.3%FY2026 +15.8%FY2026
EPS growth, the year after – +2.2% +11.9%
Revenue, next fiscal year – $50.12BFY2026 $6.61BFY2026
Revenue growth, next FY – +12.5%FY2026 +11.3%FY2026
Revenue growth, the year after – -2.7% -0.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGELSTMOSTE
Held by institutions – 90.2% 97.1%
Institutions holding – 2,627 831
Change in shares held, QoQ – +0.8% +1.1%
Institutions buying – 1,145 405
Institutions selling – 1,145 302
Buyers to sellers – 1.00 1.34

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GELSTMOSTE
GELS 1.00 0.05 -0.01
TMO 0.05 1.00 0.34
STE -0.01 0.34 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GELS, TMO and STE?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Gelteq (GELS) $2.43M, Thermo Fisher Scientific (TMO) $254.34B, Steris (STE) $25.07B.

Which stock is cheaper, GELS, TMO and STE?

Steris (STE) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.0x, Steris (STE) 30.3x). On next year's consensus earnings, Steris (STE) is cheapest (Thermo Fisher Scientific (TMO) 27.0x, Steris (STE) 22.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +8.3%, Steris (STE) +8.1%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Thermo Fisher Scientific (TMO) 14.9%, Steris (STE) 13.4%). On return on invested capital, Steris (STE) leads (Thermo Fisher Scientific (TMO) 8.0%, Steris (STE) 9.5%).

Which stock has performed better?

Over the past year Thermo Fisher Scientific (TMO) returned the most: Gelteq (GELS) -63.9%, Thermo Fisher Scientific (TMO) +19.5%, Steris (STE) +1.3%. Over five years, Steris (STE) compounded fastest (Thermo Fisher Scientific (TMO) +1.7%/yr, Steris (STE) +2.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Steris (STE) has the highest dividend yield: Gelteq (GELS) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Steris (STE) 0.01%. Gelteq (GELS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Steris (STE) has been the steadiest (Gelteq (GELS) 160.3%, Thermo Fisher Scientific (TMO) 30.7%, Steris (STE) 26.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GELS, TMO and STE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Steris (STE) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.